Hair Loss Treatments

In 1965, Minoxidil was synthesized as an oral vasodilator to treat resistant hypertension. A few years later, physicians noticed an unexpected side effect in their patients: generalized hypertrichosis. Hair was growing where it had stopped.

That detour through cardiology led to the most important discovery in modern trichology.

The mechanism of action of topical Minoxidil is well understood today. The molecule is converted locally into Minoxidil sulfate by follicular sulfotransferase — an enzyme whose activity varies significantly between individuals, which partly explains the heterogeneous treatment responses. This active metabolite works on three simultaneous fronts:

• Perifollicular vasodilation: opening of KATP potassium channels in the smooth muscle cells of perifollicular vessels, increasing the supply of oxygen and nutrients to matrix cells.
• Anagen phase extension: direct prolongation of the follicle's active growth phase, delaying the transition to the telogen phase.
• VEGF stimulation: induction of Vascular Endothelial Growth Factor synthesis by dermal papilla cells, promoting perifollicular neoangiogenesis.

What it does not do: block DHT. Minoxidil does not interfere with the androgenic hormonal cascade. This is a meaningful limitation in strongly androgen-dependent alopecias — a fact too often omitted from marketing materials.

Since 2021, low-dose oral Minoxidil (0.25 mg to 2.5 mg per day) has established itself as a serious alternative to topical application — especially for patients who tolerate topical poorly or who need diffuse coverage across the entire scalp.

The reference publication remains Sinclair et al. (2022) in the Journal of the American Academy of Dermatology: 41% of patients treated with oral Minoxidil at 1 mg/day showed overall improvement after 6 months, with a favorable tolerability profile. Piraccini et al. (2021) shows comparable results at 2.5 mg/day in women with diffuse alopecia.

Advantages of oral Minoxidil:

• No direct scalp contact — ideal if irritation or psoriasis is present
• Systemic coverage: effective on hard-to-reach zones (posterior vertex, receded temples)
• Compliance often better than twice-daily topical application
• Potentially lower cost when prescribed off-label

Side effects to monitor:

• Fluid retention and ankle swelling — the most common, generally dose-dependent and reversible upon discontinuation
• Facial hypertrichosis (face, forearms) — dose-dependent, more frequent in women at 2.5 mg
• Reflex tachycardia — rare at low doses, monitor in cardiac patients
• Orthostatic hypotension — especially at treatment onset; evening administration with food is recommended

The claim about "cardiac side effects of topical Minoxidil 5%" circulating on forums deserves clarification: systemic absorption from a correctly applied topical is under 2% of the dose. Plasma concentrations reached are too low to produce any cardiovascular effect in a healthy patient. The concern is understandable — and unfounded in standard cases. It no longer applies if you have a pre-existing cardiac condition, in which case a conversation with your cardiologist before any treatment is non-negotiable.

This is the phenomenon that causes more than half of patients to abandon treatment during their first attempt. In the first 2 to 8 weeks of Minoxidil application, hair loss accelerates. Sometimes dramatically.

This apparent worsening has a name: Minoxidil shedding. And a perfectly documented mechanism.

Minoxidil forces follicles in the telogen phase (resting) to transition into the anagen phase (growth). To initiate this new growth phase, the follicle must first expel the telogen hair still present in the sheath. This dormant hair had been there for weeks or months, held in place by the follicular structure. Anagen induction releases it — all at once.

What you observe as "worsened shedding" is actually proof that the treatment is working. Follicles are reactivating. Telogen hairs fall to make way for new growth cycles.

What you need to know:

• Duration: intense shedding typically lasts between 2 and 8 weeks, with an average around 3 to 4 weeks
• Intensity: variable depending on the proportion of follicles in the telogen phase at treatment initiation — the more advanced the alopecia, the more pronounced the shedding can be
• Red flags: shedding that extends beyond 3 months without visible improvement, patches of irritated skin or persistent crusting — these signs warrant a dermatology consultation
• Golden rule: do not evaluate Minoxidil's effectiveness before 4 months of continuous treatment. Any assessment before this point is premature

Finasteride acts where Minoxidil doesn't. It's a selective inhibitor of type II 5α-reductase — the enzyme responsible for converting testosterone into dihydrotestosterone (DHT) at the scalp. By blocking this conversion, it removes DHT's ability to attack sensitive follicles and trigger their progressive miniaturization.

The randomized clinical trial numbers are compelling: after two years at 1 mg/day, 66% of treated men stabilize their alopecia, and 48% show visible improvement in density. These aren't marketing claims — this is the Mella et al. (2010) meta-analysis, published in the Journal of the American Academy of Dermatology.

Expected results by timeline:

• 3 months: stabilization of hair loss in the majority of cases. No visible regrowth at this stage.
• 6 months: first signs of regrowth in areas of early miniaturization. Overall density stabilized.
• 12 months: most significant results. This is the standard efficacy evaluation timepoint in clinical studies.
• 24 months and beyond: maintenance of gains achieved. Stopping Finasteride leads to a gradual return to baseline over 6 to 12 months.

Finasteride is strictly contraindicated in women in its standard oral form — particularly women of childbearing age. The molecule inhibits type II 5α-reductase, an enzyme essential for the development of male genitalia in the fetus. Handling crushed tablets or cutaneous exposure is sufficient to present a teratogenic risk.

This is the topic that creates the most hesitation. And the most misinformation.

Sexual side effects of Finasteride — decreased libido, erectile dysfunction, ejaculatory disorders — exist. They are documented. Their frequency in controlled clinical trials is 1.8 to 3.8% depending on the study. These effects are generally reversible upon discontinuation, and resolve in the vast majority of affected patients.

What is less often cited: in double-blind placebo-controlled trials, the placebo group reports sexual side effects at rates between 1.3 and 2.1%. The gap from the Finasteride group is real but far more modest than online discussions suggest.

The nocebo phenomenon — the appearance of negative symptoms induced solely by the expectation of those symptoms — is well documented in pharmacology. A study published in the Journal of Sexual Medicine in 2007 (Mondaini et al.) showed that men informed of possible sexual side effects experienced 3.5 times more adverse events than those who hadn't been informed. This isn't a reason not to be informed — it's a reason to contextualize information with real statistical data.

Post-Finasteride Syndrome (PFS) — persistent side effects after discontinuation — is a more controversial entity, recognized by some experts and disputed by others. Its frequency is estimated at less than 0.5% in available publications. If you observe effects persisting more than 3 months after stopping, an endocrinology consultation is warranted.

What you can do to minimize risk:

• Start at the lowest dose (0.5 mg/day) and titrate up if well tolerated
• Consider topical Finasteride — with significantly reduced systemic absorption — as a first-line option
• Monitor your hormonal panel (total and free testosterone, PSA) at treatment initiation
• Avoid reading online forums before you have your own baseline data — confirmation bias there is massive

Topical Finasteride — gel, lotion, or nanoemulsion — represents a meaningful advance for patients who want the molecule's benefits with minimized systemic exposure.

The pharmacokinetic studies are telling. A topical application of 0.1% Finasteride generates a reduction in local DHT similar to the oral route, but with 40 to 60 times less plasma Finasteride. Blood concentration reached is often below the detection threshold.

The key clinical study: Hajheydari et al. (2009) in the Journal of the European Academy of Dermatology and Venereology shows comparable efficacy between 1% topical and 1 mg oral on hair count at 12 months, with a near-zero incidence of sexual side effects in the topical group.

Limitations to be aware of:

• In the US and UK, topical Finasteride has no FDA or MHRA approval. It is available via compounding pharmacies or through specialized telehealth platforms (Hims, Keeps, Ro).
• The stability of compounded formulations varies — prefer formulations validated by specialized laboratories.
• Onset of action is identical to the oral route: minimum 3 months to observe stabilization.

Combined topical formulations of Minoxidil + Finasteride (notably Spectral DNC-N gel or compounded formulations) are attracting growing attention in the trichology community. Preliminary results are encouraging for patients seeking a fully topical approach.

The question comes up in every consultation: "Does Saw Palmetto for hair growth actually work?" The honest answer is nuanced.

Saw palmetto (Serenoa repens) is the most studied natural 5α-reductase inhibitor. A 2020 meta-analysis published in the Journal of Drugs in Dermatology covers 7 clinical trials. The results: modest effect on hair density at 6 months, significantly inferior to Finasteride 1 mg/day in direct comparison. Not useless. Not transformative.

Ketoconazole 2% deserves special mention. A staple antifungal in shampoos (Nizoral), it also exhibits meaningful local anti-androgenic activity. A study by Pierard-Franchimont et al. (1998) in Dermatology shows a density effect comparable to Minoxidil 2% over 6 months. Probable mechanism: partial inhibition of scalp androgen synthesis and perifollicular anti-inflammatory effect.

DHT blocker hierarchy of evidence:

• Level 1 — Oral Finasteride 1 mg/day: efficacy documented in Phase III clinical trials, FDA-approved for male androgenetic alopecia
• Level 2 — Oral Dutasteride 0.5 mg/day: inhibits both 5α-reductase isoforms (type I and II), superior to Finasteride in direct comparison in Gubelin Harcha et al. (2014). Off-label prescription for hair loss in the US.
• Level 3 — Ketoconazole 2% shampoo: demonstrated local anti-androgenic activity. Use 2 to 3 times per week with a 3-minute leave-in time.
• Level 4 — Saw Palmetto (320 mg/day): modest effect, excellent safety profile, can complement a topical protocol for patients who decline oral medication.
• Level 5 — Green tea (EGCG), pumpkin seed oil, zinc: preliminary in vitro data or small-cohort studies. Complementary interest, no replacement evidence.

When a 1 mm needle penetrates the papillary dermis, it creates a micro-channel approximately 0.1 mm in diameter. Within 72 hours, that channel has closed. In the meantime, something remarkable happens.

The injury — even microscopic — triggers a controlled inflammatory cascade identical to the wound-healing mechanism. Platelets aggregate and release their alpha granules, flooding the follicular micro-environment with a high concentration of growth factors:

• VEGF (Vascular Endothelial Growth Factor): neoangiogenesis, improved oxygen and nutrient delivery to matrix cells
• PDGF (Platelet-Derived Growth Factor): dermal papilla cell proliferation — the orchestrator of the follicular cycle
• IGF-1 (Insulin-like Growth Factor-1): follicular keratinocyte survival, anagen phase extension
• Wnt/β-catenin: activation of the fundamental follicular cycle signaling pathway, first discovered in transgenic mouse baldness studies and now confirmed in humans
• KGF (Keratinocyte Growth Factor): direct stimulation of hair matrix cell proliferation

But that's not all. The micro-traumatic channels created by the needles serve as transepidermal penetration pathways for topicals applied within 24 to 48 hours following the session. Pharmacokinetic studies measure an increase in Minoxidil penetration of 4 to 8 times after scalp microneedling compared to standard application — an effect that persists 24 to 72 hours until the channels close completely.

The pivot study: Dhurat et al. (2013) in the Journal of Cutaneous and Aesthetic Surgery is the definitive reference: 100 patients randomized into two groups — Minoxidil 5% alone vs Minoxidil 5% + weekly dermaroller. Result at 12 weeks: hair count increase of 91.4 units in the dermaroller group vs 22.2 units in the Minoxidil-only group. No difference in tolerability. The synergistic effect is real and massive.

These are not interchangeable tools. Each has its structural advantages, preferred indications, and specific risks.

The Dermaroller is the most widespread. A rotating cylinder covered in needles that rolls across the scalp. Fast to use, covers large areas in minutes. Its technical disadvantage is inherent to its rolling mechanism: the needle enters the skin at an oblique angle (~45°) and exits at 45° in the other direction. This V-shaped movement creates micro-lacerations slightly wider than straight perforations, and generates more erythema for the same nominal depth.

The Derma Stamp works differently. Needles penetrate perpendicularly — at 90° to the surface — through a vertical stamping mechanism. The perforation is cleaner, the effective depth more precise, and lateral tissue trauma is minimal. For difficult-to-reach zones — receded temples, frontal hairline, deepened corners — it is superior in precision.

Comparison table:

The ideal combination for a complete protocol: a dermaroller for monthly maintenance across the entire scalp, and a derma stamp for bi-monthly targeted sessions on areas of active thinning (corners, advanced vertex).

This is the question that comes up most on hair loss forums — and generates the most confusion. The right needle length depends on your goal, your tolerance, and above all what you understand about scalp anatomical depths.

The scalp is structurally different from other skin. The epidermis is relatively thin (0.1–0.3 mm), but the papillary dermis — where follicular dermal papillae and nourishing vessels are concentrated — starts between 0.3 and 0.6 mm deep depending on the zone. The follicular bulb itself sits between 3 and 5 mm — well beyond the reach of at-home microneedles.

What you're targeting with a scalp dermaroller is not the bulb. It's the perifollicular micro-environment: the dermal papilla, perifollicular blood vessels, and stromal cells that chemically communicate with the keratinocytes of the follicular root sheath.

0.5 mm — The starting length and maintenance standard:

• Penetrates the superficial dermis without reaching deep vascularized zones
• Stimulates local growth factor production at sub-maximal but sufficient levels to increase topical penetration
• Minimal discomfort across most scalp zones
• Can be used 2 to 3 times per week without over-inflammation
• Ideal for: beginners, sensitive scalps, maintenance between 1 mm sessions, women

1 mm — The right compromise for regular at-home use:

• Penetrates the mid papillary dermis — zone of maximum concentration of follicular dermal papillae
• VEGF, PDGF, and IGF-1 release at clinically significant levels per Dhurat et al. studies
• Moderate to intense discomfort depending on the zone — vertex generally well tolerated, temples more sensitive
• Recommended frequency: maximum once per week (leave 5 to 7 days for inflammatory recovery)
• Ideal for: men with active androgenetic alopecia, standard weekly use

1.5 mm — Maximum depth for at-home use:

• Reaches the reticular dermis, releasing a more intense inflammatory response
• Potentially superior results — but at the cost of increased irritation risk and post-inflammatory hyperpigmentation on medium to dark skin tones
• Requires 7 to 14 days recovery between sessions
• Avoid on already inflamed areas, scalps with active seborrheic dermatitis, or sensitive skin
• Ideal for: once monthly on heavily thinned zones, as a complement to a weekly 0.5–1 mm protocol

This is where most DIY protocols found online go wrong. And that's a shame, because the order and timing of applications largely determines the results obtained.

Fundamental rule: never apply Minoxidil immediately after scalp microneedling.

Here's why. Microneedling creates open channels in the dermis. If you apply Minoxidil (solution or foam, which contains excipients like ethyl alcohol, propylene glycol, or surfactants) into these open channels, systemic penetration increases massively. You go from a standard systemic passage below 2% to a potentially 10 to 20 times higher passage. The cardiovascular effects that are theoretically negligible with a standard topical can become clinically significant.

Cases of tachycardia, edema, and vasovagal episodes have been documented in users who applied oral or high-concentration Minoxidil immediately after a 1.5 mm dermaroller session. This is not a negligible statistic — it's a real and preventable risk.

The validated synergy protocol:

• Day 0 — Microneedling session: clean dry scalp, 10 to 15 minutes of rolling or stamping depending on tool. Clean the tool immediately with 70% alcohol. Optionally apply a soothing serum (aloe vera, panthenol, diluted copper peptides) — without Minoxidil.
• Day 0 + 24h to 48h: micro-traumatic channels are in active remodeling, partially open. This is the optimal synergy window. Apply your Minoxidil normally, with a slight dose reduction if you notice increased sensitivity.
• Days 0 + 2 to 0 + 6: normal topical routine. The scalp is in recovery. No new microneedling before Day 7 (for 1 mm) or Day 14 (for 1.5 mm).

Tool sterilization is a critically underestimated point. A poorly cleaned dermaroller is a vector for folliculitis and scalp infection. The minimum protocol after each use:

• Immediate rinse under hot running water to remove biological residue
• 10-minute immersion in 70% isopropyl alcohol solution (not 90% — the lower concentration is more bactericidal)
• Air-dry in a clean case — never with paper towel, which leaves fibers in the needles
• Replace needles after 3 to 5 uses (titanium) or 1 to 2 (surgical steel) — dull needles tear tissue instead of perforating cleanly

Saw Palmetto (Serenoa repens) is the most documented natural 5α-reductase inhibitor to date. The berries of the Florida saw palm contain free fatty acids and phytosterols capable of inhibiting the enzyme responsible for converting testosterone into DHT — the molecule that miniaturizes sensitive follicles.

The direct comparison with Finasteride exists. The Rossi et al. (2012) study, published in the International Journal of Immunopathology and Pharmacology, followed 100 men over two years. Result: 68% improvement in hair density in the Finasteride 1 mg/day group, versus 38% in the Saw Palmetto 320 mg/day group standardized to 85–95% free fatty acids. Not bad. But the gap is real, and in a condition where every follicle counts, 30 points of difference is significant.

What Saw Palmetto offers that Finasteride doesn't: an impeccable clinical safety profile. No documented sexual side effects in controlled trials. No post-treatment syndrome. For patients who refuse Finasteride on principle — or who want a cautious entry point before considering the pharmaceutical route — it's a coherent first step in a multi-target protocol.

What matters for dosage:

• Lipophilic extract standardized to 85–95% free fatty acids — this is the form tested in studies. Aqueous or non-standardized extracts have significantly lower biological activity.
• Effective dose: 320 mg/day, in two 160 mg doses with meals. "Hair complex" supplements containing 30 or 50 mg of Saw Palmetto diluted in a blend of 15 ingredients don't reach the therapeutic dose.
• Onset of action: 3 to 6 months minimum for objective evaluation — as with Finasteride, patience is non-optional.
• Possible interaction with anticoagulants (documented antiplatelet activity) — inform your physician if you take warfarin or therapeutic-dose aspirin.

Rosemary essential oil (Salvia rosmarinus, 1,8-cineole chemotype) became the star of hair-growth essential oils after the publication of a 2015 study by Panahi et al. in Skinmed. The study compares rosemary oil vs Minoxidil 2% on 100 patients for 6 months. Result: no statistically significant difference between the two groups in hair count.

The conclusion that circulated online: "rosemary oil is as effective as Minoxidil." The honest version: it showed results comparable to Minoxidil 2% (not 5%) in a single study with methodological limitations. This study is encouraging — not definitive. It does not justify replacing a pharmaceutical protocol with an aromatic routine.

The biologically plausible mechanism: 1,8-cineole inhibits platelet thromboxane synthase and locally stimulates prostaglandin E2, promoting perifollicular vasodilation. More circulation = more nutrient delivery to the follicle. This explains an effect on reactive telogen effluvium. It doesn't explain how the oil would rival Minoxidil 5% on Stage IV androgenetic alopecia.

Pumpkin seed oil: the phytosterols it contains — particularly beta-sitosterol — partially inhibit type II 5α-reductase. A 2014 study (Cho YH et al., Evidence-Based Complementary and Alternative Medicine) on 76 men shows a +40% hair count gain versus +10% for placebo after 24 weeks, with 400 mg standardized extract per day. Small cohort, but the first level of randomized controlled evidence available for this plant.

Peppermint oil: peppermint essential oil (high menthol content) activates TRPM8 channels in follicular cells, triggering intracellular calcium influx that potentially stimulates the anagen transition. An animal model study (Oh JY et al., 2014, Toxicological Research) is favorable. Transfer to humans in androgenetic alopecia remains to be confirmed in well-designed controlled trials.

Realistic place in a protocol:

• As a complement to a foundational treatment (Minoxidil, Finasteride) for patients who want to enrich their routine without high additional costs
• As a temporary first-line option for very early stages (Norwood I–II, Ludwig I) or profiles with pharmaceutical contraindications
• Mandatory dilution: 2–3% in a carrier oil (jojoba, argan, hemp) — never undiluted on the scalp
• Caution: Rosemary oil contraindicated in the 1st trimester of pregnancy; Peppermint oil not recommended during breastfeeding

Photobiomodulation — or Low-Level Laser Therapy (LLLT) — acts on the mitochondrial respiratory chain. Red light photons (650–670 nm) or near-infrared (810 nm) are absorbed by cytochrome c oxidase, the final enzyme of the electron transport chain, triggering an increase in ATP synthesis in follicular cells.

More ATP in dermal papilla cells = more energy available for cellular proliferation, growth factor synthesis, and prolonged maintenance of the anagen phase. The mechanism is elegant, reproducible in vitro, and confirmed in vivo in several controlled trials.

The pivot study: Lanzafame et al. (2013), published in Lasers in Surgery and Medicine. 44 men with androgenetic alopecia stage Hamilton-Norwood II to V, 26 weeks of LLLT at 650 nm, 2 sessions per week. Result: hair count increase of +39% in the treatment group versus +11% in the placebo group. No documented side effects.

The Jimenez et al. (2014) trial in Lasers in Medical Science, conducted on 122 mixed-gender patients, confirms significant density improvements with excellent tolerability at 26 weeks. LLLT is particularly interesting for profiles who can't — or won't — use classical pharmaceutical treatments.

What to know before buying a laser helmet:

• FDA clearance: devices with Class II FDA clearance have provided clinical safety and efficacy data. This is the minimum criterion to verify. "Red LED" helmets sold without medical accreditation often have no published clinical data.
• Wavelength: 650–670 nm for the photobiomodulation effect documented in trichology literature. Devices at 630 nm or 700 nm have less robust data.
• Light density: between 4 and 6 mW/cm² is the documented therapeutic range. Too low: no effect. Too high: risk of paradoxical photoinhibition.
• Frequency: minimum 3 sessions per week, 20 to 30 minutes per session. Effects begin to manifest after 16 to 26 weeks of regular treatment — not before.

Platelet-Rich Plasma (PRP) is an autologous injection technique. Your own blood is drawn, centrifuged to concentrate platelets to 5–8 times their baseline level, then reinjected into the thinning zones of the scalp. The platelets release an overdose of growth factors (PDGF, VEGF, IGF-1, EGF, FGF) directly into the follicular micro-environment.

It's the same principle as scalp microneedling — but with a concentrate of endogenous growth factors injected at the source, bypassing the intermediate mechanical trauma.

The Gkini et al. (2014) study, published in the Journal of Cutaneous and Aesthetic Surgery: 46 patients with androgenetic alopecia, 3 initial PRP sessions at 1-month intervals followed by a maintenance session at 6 months. Result at 12 months: 33.6% increase in follicular density and 45.9% increase in hair count. A Gentile et al. (2019) meta-analysis grouping 11 controlled studies confirms the statistically significant benefit of PRP on hair density, with result heterogeneity linked to variability in preparation protocols.

What nobody tells you before the first session:

• The pain is real. Scalp injections — particularly at the temples, frontal hairline, and vertex — are significantly painful, even with surface anesthesia. Expect 20 to 40 injections per session depending on the surface treated. Not the same as a blood draw — a diffuse, persistent pain lasting 20 to 40 minutes.
• The alopecia stage strongly conditions the response. Norwood II–IV respond well. Norwood V–VI with advanced fibrosis respond poorly — PRP cannot resurrect a definitively fibrosed follicle. The ideal candidate is someone who still has functional but miniaturized follicles.
• The preparation protocol is decisive. Centrifugation speed, the presence of an activator (calcium chloride, autologous thrombin), and the reinjected volume directly influence the final platelet concentration. Ask your practitioner their target platelet concentration — efficacy begins around 1 million platelets/µL.
• The cost is significant: $400 to $800 per session depending on the clinic and protocol. Minimum protocol: 3 initial sessions + 1 maintenance at 6 months. Total budget over 12 months: $1,600 to $3,200.